Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Inhibition of the Phosphatidylinositol 3′-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells in Vitro and in Vivo

Victor M. Bondar, Bridget Sweeney-Gotsch, Michael Andreeff, Gordon B. Mills and David J. McConkey
Victor M. Bondar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bridget Sweeney-Gotsch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Andreeff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon B. Mills
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. McConkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Total and activated (phosphorylated on serine 473) AKT protein levels in human pancreatic cancer cells. A, paired samples of serum-starved cells at 75–80% confluence were incubated with or without 1 μm wortmannin for 1 h and lysed in a buffer containing 1% Triton, 150 mm NaCl, and 25 mm Tris-acetate (pH 7.4) supplemented with protease and phosphatase inhibitors. Proteins were resolved by 10% SDS-PAGE and detected with specific primary antibodies. Results are representative of three independent experiments. B, analysis of PTEN protein expression. Lysates were resolved by 10% SDS-PAGE, and PTEN was detected by immunoblotting. Blots were then stripped and reprobed with a rabbit polyclonal antiactin antibody (from Sigma) to confirm equal protein loading. The human HT-29 colon adenocarcinoma line contains wild-type PTEN and served as a positive control. Although PTEN protein was detected in all of the cell lines, note that the lowest levels were observed in the line (Hs766T) that demonstrated low constitutive AKT phosphorylation.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Sensitivity of human pancreatic carcinoma cells to the treatment with PI3k inhibitors. Cells maintained in MEM with 5% FBS were incubated with or without wortmannin and LY294002 for 48 h. The cells were collected with 0.25% trypsin/0.02% EDTA, and apoptosis was measured by propidium iodide staining and flow cytometry. All experiments were performed in triplicate. Data were expressed as mean; bars, ± SD. A, treatment with wortmannin and LY294002 resulted in a dose-depended apoptotic cell death in the Colo-357-L3.6pl and Panc-1 cell lines. B, PI3k inhibitors were less effective in the treatment of the CFPAC-1, HPAF, CAPAN-2, and MiaPaCa-2 cells, and failed to induce apoptosis in the AsPc-1, Hs766T, and BxPc-3 pancreatic carcinoma cells.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Analysis of ERK phosphorylation in pancreatic cancer cell lines. A, ERK phosphorylation in AsPC-1 and BxPC-3. Cells were either maintained in complete MEM or preincubated in serum-free MEM for 24 h. Cells were then incubated with or without 10 mm PD98059 for 1 h. Finally, one pair of serum-starved plates was incubated with 100 ng/ml EGF for 10 min. Cells were harvested and lysed, and levels of total and phosphorylated ERKs were measured by immunoblotting as described in “Materials and Methods.” B, effects of PD98059 on ERK and AKT phosphorylation in L3.6pl and Mia PaCa-2. Cells were preincubated in serum-free MEM before incubation with PD98059 and/or EGF as described above. Cells were harvested and lysed, and levels of total and phosphorylated ERKs and AKT were measured by immunoblotting as described in “Materials and Methods.”

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Effects of PD98059 on DNA fragmentation associated with apoptosis. AsPC-1, BxPC-3, and Mia PaCa-2 cells (75–80% confluent) were exposed to the indicated concentrations of PD98059 for 48 h, and DNA fragmentation was measured by propidium iodide staining and FACS analysis as described in “Materials and Methods.” Similar results were obtained when these cell lines were exposed to drug in serum-free medium. L3.6pl cells were grown to 80% confluence in complete medium. The medium was then replaced with serum-free complete MEM, and cells were exposed to the indicated concentrations of PD98059 in this medium for 48 h before analysis of DNA fragmentation by propidium iodide staining and FACS analysis. Similar results were obtained in two independent experiments.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Proliferation and apoptosis in orthotopic tumor xenografts. Mice bearing established (7-day) orthotopic L3.6pl tumors were treated biweekly with 100 mg/kg LY294002 via i.p. injection. After 4 weeks of therapy, animals were sacrificed, and excised tumors were analyzed by H&E staining, expression of Ki-67 antigen, or apoptosis as described in “Materials and Methods.”

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Determination of AKT and activated AKT in pancreatic cancer xenografts. Mice bearing s.c. L3.6pl tumors were treated with 100 mg/kg LY294002 via biweekly i.p. injection. Mice were sacrificed after 4 weeks, and levels of total and phosphorylated (S473) AKT were measured by immunohistochemistry. Note that LY294002 therapy reduced levels of phosphorylated AKT to background levels, whereas the effects of therapy on total AKT levels were much less pronounced, confirming drug targeting in vivo.

Tables

  • Figures
  • Table 1

    Therapy of human pancreatic carcinoma growing in the pancreas of nude mice

    One million Colo-357-L3.6pl cells were injected into the pancreas of nude mice. Seven days later, the mice were randomly assigned to four treatment groups of 10 mice each. The first group received twice-weekly i.p. injections of 5% DMSO in HBSS as control. The second, third, and fourth groups received twice-weekly i.p. injections of LY294002 at 10, 25, and 100 mg/kg. All mice were sacrificed after 4 weeks of treatment.

    Treatment groupsTumor weight in milligrams Mean ± SDLymph nodes metastasesLiver metastasesPeritoneal carcinomatosisBody weight in grams Mean ± SD
    BeforeAfter
    Control921.7 ± 266.810/109/104/1026.54 ± 2.6226.45 ± 2.36
    LY294002 10 mg/kg826.1 ± 221.59/98/93/926.13 ± 2.4527.98 ± 2.54
    LY294002 25 mg/kg740.8 ± 214.69/108/103/1026.87 ± 2.9829.08 ± 3.04
    LY294002 100 mg/kg615.3 ± 184.5a8/105/101/1026.64 ± 2.4329.04 ± 2.89
    • ↵a P < 0.005 versus control.

  • Table 2

    Therapy of human pancreatic carcinoma growing subcutaneously in nude mice

    One million of Colo-357-L3.6pl cells were mixed with Matrigel (3.5 mg of Matrigel in 0.5 ml of HBSS). Each mouse underwent two s.c. injections in bilateral flank regions. Seven days later, the mice were randomly assigned to four treatment groups of 5 mice each. The first group received twice-weekly i.p. injections of LY294002 at 25 mg/kg, the second group received gemcitabine at 62 mg/kg, the third group received combination of 25 mg/kg LY294002 and 62 mg/kg gemcitabine, and the last group received 5% DMSO in HBSS as control. All mice were sacrificed after 3 weeks of treatment.

    Treatment groupsTumor volume in mm3 Mean ± SD
    Body weight in grams Mean ± SD
    BeforeAfterBeforeAfter
    Control191.8 ± 76.92314.1 ± 874.823.12 ± 3.1827.52 ± 3.26
    Gemcitabine 62 mg/kg183.9 ± 67.61596 ± 350.1a23.66 ± 2.8728.18 ± 2.54
    LY294002 25 mg/kg175 ± 41.11738.1 ± 387.423.09 ± 3.0828.27 ± 3.34
    LY294002 25 mg/kg + Gemcitabine 62 mg/kg181.3 ± 51.31071.4 ± 224.3b22.92 ± 2.7829.3 ± 3.01
    • ↵a P < 0.025 versus control.

    • ↵b P < 0.0005 versus all other groups.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 1 (12)
October 2002
Volume 1, Issue 12
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of the Phosphatidylinositol 3′-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells in Vitro and in Vivo
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibition of the Phosphatidylinositol 3′-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells in Vitro and in Vivo
Victor M. Bondar, Bridget Sweeney-Gotsch, Michael Andreeff, Gordon B. Mills and David J. McConkey
Mol Cancer Ther October 1 2002 (1) (12) 989-997;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Inhibition of the Phosphatidylinositol 3′-Kinase-AKT Pathway Induces Apoptosis in Pancreatic Carcinoma Cells in Vitro and in Vivo
Victor M. Bondar, Bridget Sweeney-Gotsch, Michael Andreeff, Gordon B. Mills and David J. McConkey
Mol Cancer Ther October 1 2002 (1) (12) 989-997;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement